MiR-192 serving as specificity biomarker for early diagnosis of diabetic kidney disease and application of MiR-192

Abstract

The invention creatively provides miR-192 serving as a specificity biomarker for early diagnosis of a diabetic kidney disease and application of the MiR-192. The adopted technical scheme is as follows: application of the miR-192 in the serum to the early clinical specificity diagnosis of the diabetic kidney disease uses qRT-PCR to detect miRNA-192 in the serum to diagnose the diabetic kidney disease; application of the miR-192 in the urine to the early clinical specificity diagnosis of the diabetic kidney disease uses qRT-PCR to detect miRNA-192 in the urine to diagnose the diabetic kidney disease, a critical point of the miRNA-192 used for diagnosing the early diabetic kidney disease is provided, application of the miRNA marker is used to prepare an early diagnosis agent or kit for detecting the diabetic kidney disease, and application of the miRNA marker is used to prepare an early diagnosis agent or kit for detecting the diabetic kidney disease. A novel diagnosis means is provided for the clinical diagnosis of the diabetic kidney disease, and the miR-192 and the application of the miR-192 have certain potential clinical values for the adjuvant treatment and the course monitoring of the diabetic kidney disease (DKD).

Description

technical field [0001] The present invention relates to the application of miR-192 as a specific biomarker in the early diagnosis of diabetic nephropathy. [0002] technical background [0003] Diabetic kidney disease (DKD), also known as diabetic nephropathy (DN), is a common microvascular complication in patients with diabetes mellitus (DM). The kidney damage caused by it involves not only blood vessels, glomeruli, and renal tubules, but also almost all renal structures such as renal interstitium and podocytes. [0004] At present, the main standard for the diagnosis of DKD is to measure the 24-hour urinary protein quantification or the urinary microalbuminuria excretion rate in the overnight period. However, once microalbuminuria is detected clinically, substantial damage to the kidneys already exists, and the glomerular function will be progressive. Irreversible decline; clinically, some DM patients with urinary albumin within the normal range have actually experienced a...

AI Technical Summary

Problems solved by technology

[0004] At present, the main standard for the diagnosis of DKD is to measure the 24-hour urinary protein quantification or the urinary microalbuminuria excretion rate in the overnight period. However, once microalbuminuria is detected clinically, substantial damage to the kidneys already exists, and the glomerular function will be progressive. Irreversible decline; clinically, some DM patients with urinary albumin within the normal range have actually experienced a decline in glomerular filtration rate, and characteristic changes related to DKD will also be found in renal pathology; existing clinical treatments It can only slow down the progression of DKD to renal failure, but it is far from reversing the course of the disease

Images